Nyirjesy Paul, McIntosh Matthew J, Steinmetz Jana I, Schumacher Robert J, Joffrion James L
Department of Obstetrics and Gynecology, Drexel University College of Medicine, Philadelphia, PA 19102, USA.
Sex Transm Dis. 2007 Apr;34(4):197-202. doi: 10.1097/01.olq.0000235152.98601.d7.
The objective of this study was to compare the effects of treatments for bacterial vaginosis (BV) on vaginal Mobiluncus morphotypes.
Analyses were performed on Mobiluncus scores from similarly conducted studies evaluating clindamycin vaginal single-dose cream (CVSDC) or metronidazole vaginal gel (MVG) in 55 patients with BV and with Mobiluncus morphotypes at baseline.
Both treatment groups demonstrated significant reductions in Mobiluncus score. However, the Mobiluncus score at test-of-cure was lower in the CVSDC than in the MVG group (P=0.0471). More patients in the CVSDC group than in the MVG group achieved microbiologic (57.5% vs. 26.7%; P=0.04), clinical (57.5% vs. 26.7%; P=0.04), and therapeutic cures of BV (45.0% vs. 20.0%; P=0.09).
Clindamycin reduces vaginal Mobiluncus morphotypes to a greater extent than metronidazole in patients with BV; this correlates with a higher BV cure rate.
本研究的目的是比较细菌性阴道病(BV)治疗方法对阴道动弯杆菌形态型的影响。
对来自类似研究的动弯杆菌评分进行分析,这些研究评估了55例基线时有动弯杆菌形态型的BV患者使用克林霉素阴道单剂量乳膏(CVSDC)或甲硝唑阴道凝胶(MVG)的情况。
两个治疗组的动弯杆菌评分均显著降低。然而,治愈测试时CVSDC组的动弯杆菌评分低于MVG组(P = 0.0471)。CVSDC组实现微生物学治愈(57.5%对26.7%;P = 0.04)、临床治愈(57.5%对26.7%;P = 0.04)和BV治疗性治愈(45.0%对20.0%;P = 0.09)的患者比MVG组更多。
在BV患者中,克林霉素比甲硝唑更能有效减少阴道动弯杆菌形态型;这与更高的BV治愈率相关。